Cti Biopharma Corp Stock Gross Profit
CTICDelisted Stock | USD 9.09 0.00 0.00% |
CTi Biopharma Corp fundamentals help investors to digest information that contributes to CTi Biopharma's financial success or failures. It also enables traders to predict the movement of CTi Stock. The fundamental analysis module provides a way to measure CTi Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CTi Biopharma stock.
CTi |
CTi Biopharma Corp Company Gross Profit Analysis
CTi Biopharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current CTi Biopharma Gross Profit | 50.43 M |
Most of CTi Biopharma's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTi Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, CTi Biopharma Corp reported 50.43 M of gross profit. This is 97.75% lower than that of the Biotechnology sector and 94.69% lower than that of the Health Care industry. The gross profit for all United States stocks is 99.82% higher than that of the company.
CTi Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTi Biopharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics of similar companies.CTi Biopharma is currently under evaluation in gross profit category among its peers.
CTi Fundamentals
Return On Equity | -10.19 | |||
Return On Asset | -0.29 | |||
Profit Margin | (0.91) % | |||
Operating Margin | (0.74) % | |||
Current Valuation | 1.26 B | |||
Shares Outstanding | 131.88 M | |||
Shares Owned By Insiders | 5.49 % | |||
Shares Owned By Institutions | 83.28 % | |||
Number Of Shares Shorted | 11.27 M | |||
Price To Earning | (1.68) X | |||
Price To Book | 112.63 X | |||
Price To Sales | 22.01 X | |||
Revenue | 53.95 M | |||
Gross Profit | 50.43 M | |||
EBITDA | (79.85 M) | |||
Net Income | (92.99 M) | |||
Cash And Equivalents | 81.64 M | |||
Cash Per Share | 0.64 X | |||
Total Debt | 49.96 M | |||
Current Ratio | 3.26 X | |||
Book Value Per Share | (0.19) X | |||
Cash Flow From Operations | (81.19 M) | |||
Short Ratio | 1.08 X | |||
Earnings Per Share | (0.54) X | |||
Target Price | 10.05 | |||
Number Of Employees | 127 | |||
Beta | 0.83 | |||
Market Capitalization | 1.2 B | |||
Total Asset | 125.92 M | |||
Retained Earnings | (2.52 B) | |||
Working Capital | 18.26 M | |||
Current Asset | 134.97 M | |||
Current Liabilities | 72.41 M | |||
Z Score | -15.1 | |||
Net Asset | 125.92 M |
About CTi Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTi Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |